CMSC Tuesday, March 16 2010
CMSC Online

« < March 2010 > »
S M T W T F S
28 1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31 1 2 3


 
Home arrow CMSC Online arrow For MS Professionals arrow Presentations
Multidisciplinary Team in MS Print E-mail

The Multidisciplinary Team in Multiple Sclerosis


This activity has expired. The accredited provider can no longer issue certificates for this activity. CMSC provides this for informational purposes only and cannot attest to the timeliness of expired CME/CE activities.

ACTIVITY GOAL
Multidisciplinary (MD) care for multiple sclerosis (MS) is an important element of supportive treatment to improve patients' quality of life. The team approach can facilitate a greater breadth and depth of comprehensive, continuous care for the MS patient in a coordinated, interdisciplinary fashion. Visit this activity to see a panel of thought leaders discuss the multidisciplinary management of multiple sclerosis.

Release Date: August 18, 2008; Valid for credit through August 18, 2009

Credits Available
Physcians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 ANCC contact hours (None of these credits is in the area of pharmacology)


This activity is supported by an educational grant from EMD Serono, Inc.
EMD Serono


LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:
  • Describe advances in MS diagnosis and intervention
  • Identify factors that impact quality of life and disability in patients with MS
  • Create a multidisciplinary network of collaborating providers, including nurse practitioners, physician assistants, psychologists, psychiatrists, social workers, occupational therapists, pharmacists, neuroophthalmologists, neurologists, and other practitioners who provide support for the MS patient



AUTHORS AND DISCLOSURE

Patricia K. Coyle, MD, Chairperson
Disclosure:Dr. Coyle
Sources of Funding for Research:Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Pfizer Inc; sanofi-aventis Group; Teva Neuroscience, Inc.
Consulting Agreements:BioMS Medical Corp.; EMD Serono, Inc.; Novartis Pharmaceuticals Corp; Pfizer Inc.
Speakers' Bureau/Honorarium Agreements:Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Pfizer Inc; Teva Neuroscience, Inc.
Financial Interests/Stock Ownership:None
Discussion of Off-Label, Investigational, or Experimental Drug Use:None


Bruce A. Cohen, MD
Disclosure:Dr. Cohen
Sources of Funding for Research:BioMS Medical Corp.; EMD Serono, Inc.; Novartis Pharmaceuticals Corp; Pfizer Inc.
Consulting Agreements:Bayer HealthCare Pharmaceuticals; Biogen Idec; Pfizer Inc; EMD Serono, Inc.; Teva Neuroscience, Inc.
Speakers' Bureau/Honorarium Agreements:Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.
Financial Interests/Stock Ownership:Abbott Laboratories; CVS Caremark.
Discussion of Off-Label, Investigational, or Experimental Drug Use:None


Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosure:Amy Perrin Ross
Sources of Funding for Research:None
Consulting Agreements:Bayer HealthCare Pharmaceuticals; EMD Serono, Inc.; Genentech/Biogen Idec; Novartis Pharmaceuticals Corp; Pfizer Inc; Teva Neuroscience, Inc.
Speakers' Bureau/Honorarium Agreements:Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.
Financial Interests/Stock Ownership:None
Discussion of Off-Label, Investigational, or Experimental Drug Use:None


Anthony L. Traboulsee, MD
Disclosure:Dr. Traboulsee
Sources of Funding for Research:Multiple Sclerosis Society of Canada
Consulting Agreements:Speakers' Bureau/Honorarium Agreements: Bayer HealthCare Pharmaceuticals; Biogen Idec; Teva Neuroscience, Inc.
Speakers' Bureau/Honorarium Agreements:Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.
Financial Interests/Stock Ownership:None
Discussion of Off-Label, Investigational, or Experimental Drug Use:Cladribine, fingolimod, and teriflunamide


Aaron P. Turner, PhD
Disclosure:Dr. Turner
Sources of Funding for Research:None
Consulting Agreements:None
Speakers' Bureau/Honorarium Agreements:None
Financial Interests/Stock Ownership:None
Discussion of Off-Label, Investigational, or Experimental Drug Use:None



CREDIT DESIGNATION / ACCREDITATION STATEMENT

dime

DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DIME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Discovery Institute of Medical Education (DIME) is an approved provider of continuing nursing education by the Illinois Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Participants in this activity are eligible for up to 1.0 contact hours of continuing nursing education.



LEGAL DISCLAIMER
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 DIME

Click here to view the program.




Date Created: January 8, 2009
Last Update: August 20, 2009

 

Last Updated ( Thursday, 27 August 2009 )